Halozyme Therapeutics, Inc.
LSE: 0J2O.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Helen I. Torley
- Employees
- 350
- Headquarters
- San Diego, United States
- IPO year
- 2018
- Market cap
- $7.6B
- Website
- https://www.halozyme.com
Loading 0J2O…
Loading profile data…Frequently asked questions about 0J2O
What does Halozyme Therapeutics, Inc. (0J2O.L) do?
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
Where does 0J2O.L trade?
Halozyme Therapeutics, Inc. (0J2O.L) trades on the London Stock Exchange.
What sector is 0J2O.L in?
Halozyme Therapeutics, Inc. (0J2O.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Halozyme Therapeutics, Inc.?
Helen I. Torley is the chief executive officer of Halozyme Therapeutics, Inc. (0J2O.L).
Where is Halozyme Therapeutics, Inc. headquartered?
Halozyme Therapeutics, Inc. is headquartered in United States.
Does 0J2O.L pay a dividend?
Halozyme Therapeutics, Inc. (0J2O.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0J2O.L go public?
Halozyme Therapeutics, Inc. (0J2O.L) completed its initial public offering in 2018.